Predictive factors of outcome in patients transplanted for hepatitis B

Transplantation

Volumn 87, Issue 6, 2009, Pages 872-881

  Beckebaum, Susanne ^a   Sotiropoulos, Georgios C ^a   Klein, Christian G ^a   Broelsch, Christoph E ^a   Saner, Fuat ^a   Paul, Andreas ^a   Gerken, Guido ^a   Cicinnati, Vito R ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Graft cirrhosis; Hepatitis B; Patient and graft survival; Predictors; Recurrence

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEOSIDE ANALOG; RAPAMYCIN; TACROLIMUS; VIRUS DNA; CYCLOSPORIN; HEPATITIS B HYPERIMMUNE GLOBULIN;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHOLESTASIS; CHRONIC HEPATITIS; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DRUG MEGADOSE; FOLLOW UP; GRAFT FAILURE; GRAFT SURVIVAL; HEPATITIS B; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KAPLAN MEIER METHOD; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PREDICTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; REINFECTION; REOPERATION; SEROLOGY; SURVIVAL RATE; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; VIRUS HEPATITIS; VIRUS INFECTION; ADULT; AGED; FEMALE; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; MORTALITY; PHYSIOLOGY; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RISK FACTOR; SURVIVAL; SURVIVOR;

ADULT; AGED; CARDIOVASCULAR DISEASES; CYCLOSPORINE; FEMALE; GRAFT SURVIVAL; HEPATITIS B; HUMANS; IMMUNOGLOBULINS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REGRESSION ANALYSIS; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVORS; TACROLIMUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 65549140233     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31819a6697     Document Type: Article

References (61)

1. Leonard J, Heimbach JK, Malinchoc M, et al. The impact of obesity on long-term outcomes in liver transplant recipients-results of the NIDDK liver transplant database. Am J Transplant 2008; 8: 667.
2. Rosen HR, Madden JP, Martin P. A model to predict survival following liver retransplantation. Hepatology 1999; 29: 365.
3. Doyle HR, Marino IR, Jabbour N, et al. Early death or retransplantation in adults after orthotopic liver transplantation. Can outcome be predicted? Transplantation 1994; 57: 1028.
4. Volk ML, Hernandez JC, Lok AS, et al. Modified Charlson comorbidity index for predicting survival after liver transplantation. Liver Transpl 2007; 13: 1515.
5. Ghobrial RM, Gornbein J, Steadman R, et al. Pretransplant model to predict posttransplant survival in liver transplant patients. Ann Surg 2002; 236: 315.
6. Powner DJ. Factors during donor care that may affect liver transplantation outcome. Prog Transplant 2004; 14: 241.
7. Berenguer M, Crippin J, Gish R, et al. A model to predict severe HCVrelated disease following liver transplantation. Hepatology 2003; 38: 34.
8. Iacob S, Cicinnati VR, Hilgard P, et al. Predictors of graft and patient survival in hepatitis C virus (HCV) recipients: Model to predict HCV cirrhosis after liver transplantation. Transplantation 2007; 84: 56.
9. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823.
10. Charlton M, Ruppert K, Belle SH, et al. Long-term results and modeling to predict outcomes in recipients withHCVinfection: Results of the NIDDK liver transplantation database. Liver Transpl 2004; 10: 1120.
11. Ghobrial RM, Steadman R, Gornbein J, et al. A 10-year experience of liver transplantation for hepatitis C: Analysis of factors determining outcome in over 500 patients. Ann Surg 2001; 234: 384.
12. Gane EJ, Angus PW, Strasser S, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132: 931.
13. Lake JR, Shorr JS, Steffen BJ, et al. Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. Am J Transplant 2005; 5: 549.
14. Kim WR, Poterucha JJ, Kremers WK, et al. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004; 10: 968.
15. Anselmo DM, Ghobrial RM, Jung LC, et al. New era of liver transplantation for hepatitis B: A 17-year single-center experience. Ann Surg 2002; 235: 611.
16. Wong SN, Reddy KR, Keeffe EB, et al. Comparison of clinical outcomes in chronic hepatitis B liver transplant candidates with and without hepatocellular carcinoma. Liver Transpl 2007; 13: 334.
17. Samuel D, Kimmoun E. Immunosuppression in hepatitis B virus and hepatitis C virus transplants: Special considerations. Clin Liver Dis 2003; 7: 667.
18. Tur-Kaspa R, Burk RD, Shaul Y, et al. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA 1986; 83: 1627.
19. Tur-Kaspa R, Shaul Y, Moore DD, et al. The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology 1988; 167: 630.
20. Wiesner R, Rabkin J, Klintmalm G, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001; 7: 442.
21. Kato T, Gaynor JJ, Yoshida H, et al. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: Impact on hepatic fibrosis progression at one year. Transplantation 2007; 84: 829.
22. Bahra M, Neumann UI, Jacob D, et al. MMF and calcineurin taper in recurrent hepatitis C after liver transplantation: Impact on histological course. Am J Transplant 2005; 5: 406.
23. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464.
24. Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995; 19: 1409.
25. Shen L, Li JQ, Zeng MD, et al. Correlation between ultrasonographic and pathologic diagnosis of liver fibrosis due to chronic virus hepatitis. World J Gastroenterol 2006; 12: 1292.
26. Infante-Rivard C, Esnaola S, Villeneuve JP. Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. Hepatology 1987; 7: 660.
27. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 1206.
28. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008; 31(suppl 1): S55.
29. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693.
30. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394.
31. Kim DY, Choi MS, Lee JH, et al. Older donor allografts are associated with poor patient survival after living donor liver transplantation for hepatitis B virus-related liver diseases. Liver Int 2007; 27: 260.
32. Desai NM, Mange KC, Crawford MD, et al. Predicting outcome after liver transplantation: Utility of the model for end-stage liver disease and a newly derived discrimination function. Transplantation 2004; 77: 99.
33. Wigg AJ, Gunson BK, Mutimer DJ. Outcomes following liver transplantation for seronegative acute liver failure: Experience during a 12- year period with more than 100 patients. Liver Transpl 2005; 11: 27.
34. Pelletier SJ, Schaubel DE, Wei G, et al. Effect of body mass index on the survival benefit of liver transplantation. Liver Transpl 2007; 13: 1678.
35. Hillingso JG, Wettergren A, Hyoudo M, et al. Obesity increases mortality in liver transplantation-the Danish experience. Transpl Int 2005; 18: 1231.
36. Nair S, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 2002; 35: 105.
37. Yoo HY, Molmenti E, Thuluvath PJ. The effect of donor body mass index on primary graft nonfunction, retransplantation rate, and early graft and patient survival after liver transplantation. Liver Transpl 2003; 9: 72.
38. Boin IF, Almeida LV, Udo EY, et al. Survival analysis of obese patients undergoing liver transplantation. Transplant Proc 2007; 39: 3225.
39. Nair S, Cohen DB, Cohen MP, et al. Postoperative morbidity, mortality, costs, and long-term survival in severely obese patients undergoing orthotopic liver transplantation. Am J Gastroenterol 2001; 96: 842.
40. Sawyer RG, Pelletier SJ, Pruett TL. Increased early morbidity and mortality with acceptable long-term function in severely obese patients undergoing liver transplantation. Clin Transplant 1999; 13: 126.
41. Wiesner RH. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: A report of the United States FK506 Study Group. Transplantation 1998; 66: 493.
42. Rolles K, Davidson BR, Burroughs AK. A pilot study of immunosuppressive monotherapy in liver transplantation: Tacrolimus versus microemulsified cyclosporin. Transplantation 1999; 68: 1195.
43. Gonzalez-Pinto IM, Rimola A, Margarit C, et al. Five-year follow-up of a trial comparing Tacrolimus and cyclosporine microemulsion in liver transplantation. Transplant Proc 2005; 37: 1713.
44. O'Grady JG, Hardy P, Burroughs AK, et al. Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: Poststudy surveillance to 3 years. Am J Transplant 2007; 7: 137.
45. Klein IH, Abrahams A, van ET, et al. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation 2002; 73: 732.
46. Artz MA, Boots JM, Ligtenberg G, et al. Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. Am J Transplant 2004; 4: 937.
47. Lucey MR, Abdelmalek MF, Gagliardi R, et al. A comparison of tacrolimus and cyclosporine in liver transplantation: Effects on renal function and cardiovascular risk status. Am J Transplant 2005; 5: 1111.
48. Padi SS, Chopra K. Selective angiotensin II type 1 receptor blockade ameliorates cyclosporine nephrotoxicity. Pharmacol Res 2002; 45: 413.
49. Petrakopoulou P, Anthopoulou L, Muscholl M, et al. Coronary endothelial vasomotor function and vascular remodeling in heart transplant recipients randomized for tacrolimus or cyclosporine immunosuppression. J Am Coll Cardiol 2006; 47: 1622.
50. Figueras J, Jaurrieta E, Valls C, et al. Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: A comparative study. Hepatology 1997; 25: 1485.
51. Rodriguez-Luna H, Balan V, Sharma P, et al. HepatitisCvirus infection with hepatocellular carcinoma: Not a controversial indication for liver transplantation. Transplantation 2004; 78: 580.
52. Jonas S, Bechstein WO, Steinmuller T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33: 1080.
53. Zavaglia C, De CL, Alberti AB, et al. Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol 2005; 100: 2708.
54. Bhattacharjya S, Bhattacharjya T, Quaglia A, et al. Liver transplantation in cirrhotic patients with small hepatocellular carcinoma: An analysis of pre-operative imaging, explant histology and prognostic histologic indicators. Dig Surg 2004; 21: 152.
55. Buis CI, Hoekstra H, Verdonk RC, et al. Causes and consequences of ischemic-type biliary lesions after liver transplantation. J Hepatobiliary Pancreat Surg 2006; 13: 517.
56. Guichelaar MM, Benson JT, Malinchoc M, et al. Risk factors for and clinical course of non-anastomotic biliary strictures after liver transplantation. Am J Transplant 2003; 3: 885.
57. Welling TH, Heidt DG, Englesbe MJ, et al. Biliary complications following liver transplantation in the model for end-stage liver disease era: Effect of donor, recipient, and technical factors. Liver Transpl 2008; 14: 73.
58. Raisanen-Sokolowski A, Vuoristo P, Myllarniemi M, et al. Mycophenolate mofetil (MMF, RS-61443) inhibits inflammation and smooth muscle cell proliferation in rat aortic allografts. Transpl Immunol 1995; 3: 342.
59. Blaheta RA, Leckel K, Wittig B, et al. Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells. Transplant Proc 1999; 31: 1250.
60. Shipkova M, Armstrong VW, Oellerich M, et al. Mycophenolate mofetil in organ transplantation: Focus on metabolism, safety and tolerability. Expert Opin Drug Metab Toxicol 2005; 1: 505.
61. Mamelok R. From mechanisms to long-term benefits. Transplantation 2005; 79: S43.